Valsartan
Payments companies reported to CMS as associated with Valsartan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Valsartan, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Valsartan
These are the largest totals companies reported as associated with Valsartan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Genevieve Matthews | Westwood, NJ | Internal Medicine | $34.72 |
| Edgar Camacho | Miami, FL | Nurse Practitioner | $18.50 |
| Ana Paredes | South Miami, FL | Pediatric Nephrology | $18.50 |
| Mariselis Rosa Sanchez | South Miami, FL | Pediatric Nephrology | $18.50 |
| Reuven Bromberg | Miami, FL | Rheumatology | $18.50 |
| Kimberly Anne Cooper | Westwood, NJ | Internal Medicine | $16.91 |
| Matthew Cooper | Westwood, NJ | Family Medicine | $16.91 |
| George Stoupakis | Hackensack, NJ | Cardiovascular Disease | $15.31 |
| Michael Boja | Teaneck, NJ | Family Medicine | $10.69 |
Prescribed Valsartan?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.